vs
CLOVER HEALTH INVESTMENTS, CORP.（CLOV）与罗布乐思（RBLX）财务数据对比。点击上方公司名可切换其他公司
罗布乐思的季度营收约是CLOVER HEALTH INVESTMENTS, CORP.的1.9倍（$1.4B vs $749.2M），CLOVER HEALTH INVESTMENTS, CORP.净利率更高（3.6% vs -22.3%，领先26.0%），CLOVER HEALTH INVESTMENTS, CORP.同比增速更快（62.0% vs 43.2%），过去两年CLOVER HEALTH INVESTMENTS, CORP.的营收复合增速更高（45.0% vs 32.9%）
克利弗健康投资公司是2014年成立的美国医疗保健企业，主营联邦医疗保险优势计划保险产品，是与美国政府直接签约合作的机构。目前公司为美国11个州的联邦医疗保险参保人提供健康管理服务，并已于2021年1月8日公开上市。
罗布乐思（Roblox Corporation）是总部位于美国加利福尼亚州圣马特奥的游戏企业，由大卫·巴斯祖奇与埃里克·卡塞尔于2004年共同创立。公司核心产品为同名线上游戏创作平台Roblox，于2006年正式上线，截至2024年12月底全球员工规模已超2400人。
CLOV vs RBLX — 直观对比
营收规模更大
RBLX
是对方的1.9倍
$749.2M
营收增速更快
CLOV
高出18.9%
43.2%
净利率更高
CLOV
高出26.0%
-22.3%
两年增速更快
CLOV
近两年复合增速
32.9%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $749.2M | $1.4B |
| 净利润 | $27.3M | $-316.0M |
| 毛利率 | — | 77.7% |
| 营业利润率 | 3.6% | -25.3% |
| 净利率 | 3.6% | -22.3% |
| 营收同比 | 62.0% | 43.2% |
| 净利润同比 | — | -43.9% |
| 每股收益（稀释后） | $0.05 | $-0.44 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CLOVRBLX
| Q1 26 | $749.2M | — | ||
| Q4 25 | $487.7M | $1.4B | ||
| Q3 25 | $496.6M | $1.4B | ||
| Q2 25 | $477.6M | $1.1B | ||
| Q1 25 | $462.3M | $1.0B | ||
| Q4 24 | $337.0M | $988.2M | ||
| Q3 24 | $331.0M | $919.0M | ||
| Q2 24 | $356.3M | $893.5M |
净利润CLOVRBLX
| Q1 26 | $27.3M | — | ||
| Q4 25 | $-49.3M | $-316.0M | ||
| Q3 25 | $-24.4M | $-255.6M | ||
| Q2 25 | $-10.6M | $-278.4M | ||
| Q1 25 | $-1.3M | $-215.1M | ||
| Q4 24 | $-22.1M | $-219.6M | ||
| Q3 24 | $-9.2M | $-239.3M | ||
| Q2 24 | $7.4M | $-205.9M |
毛利率CLOVRBLX
| Q1 26 | — | — | ||
| Q4 25 | — | 77.7% | ||
| Q3 25 | — | 78.2% | ||
| Q2 25 | — | 78.2% | ||
| Q1 25 | — | 78.3% | ||
| Q4 24 | — | 77.9% | ||
| Q3 24 | 24.5% | 77.7% | ||
| Q2 24 | 30.3% | 77.8% |
营业利润率CLOVRBLX
| Q1 26 | 3.6% | — | ||
| Q4 25 | -10.1% | -25.3% | ||
| Q3 25 | -4.9% | -21.8% | ||
| Q2 25 | -2.2% | -29.8% | ||
| Q1 25 | -0.3% | -24.6% | ||
| Q4 24 | -6.4% | -24.7% | ||
| Q3 24 | -2.7% | -30.4% | ||
| Q2 24 | 2.0% | -26.6% |
净利率CLOVRBLX
| Q1 26 | 3.6% | — | ||
| Q4 25 | -10.1% | -22.3% | ||
| Q3 25 | -4.9% | -18.8% | ||
| Q2 25 | -2.2% | -25.8% | ||
| Q1 25 | -0.3% | -20.8% | ||
| Q4 24 | -6.6% | -22.2% | ||
| Q3 24 | -2.8% | -26.0% | ||
| Q2 24 | 2.1% | -23.0% |
每股收益（稀释后）CLOVRBLX
| Q1 26 | $0.05 | — | ||
| Q4 25 | — | $-0.44 | ||
| Q3 25 | — | $-0.37 | ||
| Q2 25 | — | $-0.41 | ||
| Q1 25 | — | $-0.32 | ||
| Q4 24 | — | $-0.32 | ||
| Q3 24 | — | $-0.37 | ||
| Q2 24 | — | $-0.32 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $177.6M | $3.1B |
| 总债务越低越好 | — | $1.2B |
| 股东权益账面价值 | $339.4M | $394.5M |
| 总资产 | $697.7M | $9.6B |
| 负债/权益比越低杠杆越低 | — | 2.98× |
8季度趋势，按日历期对齐
现金及短期投资CLOVRBLX
| Q1 26 | $177.6M | — | ||
| Q4 25 | $78.3M | $3.1B | ||
| Q3 25 | — | $2.9B | ||
| Q2 25 | — | $2.6B | ||
| Q1 25 | — | $2.7B | ||
| Q4 24 | $194.5M | $2.4B | ||
| Q3 24 | $288.0M | $2.3B | ||
| Q2 24 | $254.8M | $2.4B |
总债务CLOVRBLX
| Q1 26 | — | — | ||
| Q4 25 | — | $1.2B | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $1.2B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
股东权益CLOVRBLX
| Q1 26 | $339.4M | — | ||
| Q4 25 | $308.7M | $394.5M | ||
| Q3 25 | $340.9M | $407.6M | ||
| Q2 25 | $344.2M | $353.2M | ||
| Q1 25 | $336.1M | $310.7M | ||
| Q4 24 | $341.1M | $221.4M | ||
| Q3 24 | $342.2M | $189.9M | ||
| Q2 24 | $324.9M | $121.5M |
总资产CLOVRBLX
| Q1 26 | $697.7M | — | ||
| Q4 25 | $541.0M | $9.6B | ||
| Q3 25 | $559.7M | $8.6B | ||
| Q2 25 | $575.0M | $7.8B | ||
| Q1 25 | $583.7M | $7.5B | ||
| Q4 24 | $580.7M | $7.2B | ||
| Q3 24 | $653.0M | $6.7B | ||
| Q2 24 | $674.2M | $6.5B |
负债/权益比CLOVRBLX
| Q1 26 | — | — | ||
| Q4 25 | — | 2.98× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 5.48× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $607.0M |
| 自由现金流经营现金流 - 资本支出 | — | $308.6M |
| 自由现金流率自由现金流/营收 | — | 21.8% |
| 资本支出强度资本支出/营收 | — | 21.1% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $1.4B |
8季度趋势，按日历期对齐
经营现金流CLOVRBLX
| Q1 26 | — | — | ||
| Q4 25 | $-66.9M | $607.0M | ||
| Q3 25 | $12.1M | $546.2M | ||
| Q2 25 | $5.4M | $199.3M | ||
| Q1 25 | $-16.3M | $443.9M | ||
| Q4 24 | $34.8M | $184.5M | ||
| Q3 24 | $50.0M | $247.4M | ||
| Q2 24 | $44.8M | $151.4M |
自由现金流CLOVRBLX
| Q1 26 | — | — | ||
| Q4 25 | $-69.0M | $308.6M | ||
| Q3 25 | $11.4M | $443.6M | ||
| Q2 25 | $4.8M | $176.7M | ||
| Q1 25 | $-16.5M | $426.5M | ||
| Q4 24 | $33.3M | $120.6M | ||
| Q3 24 | $49.6M | $218.0M | ||
| Q2 24 | $44.4M | $111.7M |
自由现金流率CLOVRBLX
| Q1 26 | — | — | ||
| Q4 25 | -14.1% | 21.8% | ||
| Q3 25 | 2.3% | 32.6% | ||
| Q2 25 | 1.0% | 16.3% | ||
| Q1 25 | -3.6% | 41.2% | ||
| Q4 24 | 9.9% | 12.2% | ||
| Q3 24 | 15.0% | 23.7% | ||
| Q2 24 | 12.5% | 12.5% |
资本支出强度CLOVRBLX
| Q1 26 | — | — | ||
| Q4 25 | 0.4% | 21.1% | ||
| Q3 25 | 0.1% | 7.5% | ||
| Q2 25 | 0.1% | 2.1% | ||
| Q1 25 | 0.0% | 1.7% | ||
| Q4 24 | 0.5% | 6.5% | ||
| Q3 24 | 0.1% | 3.2% | ||
| Q2 24 | 0.1% | 4.4% |
现金转化率CLOVRBLX
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 6.04× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
